ClinicalTrials.gg

Program

QLS12010

A development code.

Its studies are mostly in Dermatitis, Atopic · Hidradenitis Suppurativa · Arthritis, Rheumatoid, led by Qilu Pharmaceutical.

Furthest: phase 2, since Jan 7, 20264 company-led studies, 4 open or runningNext primary completion: Jun 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical44 open or runningphase 2since Jan 7, 2026Mar 30, 2025Jun 1, 2027phase 2 · NCT07417917

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2025First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06946641 · 102 planned · China
  2. Jan 7, 20262 phase 2 studiesPhase 2 reachedNCT07344051, NCT07377773
  3. Feb 11, 2026Phase 2 study in Adults With Moderate-to-severe Hidradenitis SuppurativaNCT07417917 · 102 planned

Ahead

  1. Jun 1, 2027Primary completion: phase 2 study in Adults With Moderate-to-severe Hidradenitis SuppurativaNCT07417917
  2. Sep 2027Primary completion: phase 2 study in Moderate-to-severe Atopic DermatitisNCT07344051
  3. Mar 5, 2028Primary completion: phase 2 study in Arthritis, RheumatoidNCT07377773

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07417917Adults With Moderate-to-severe Hidradenitis Suppurativa2Not yet recruitingJun 1, 2027102
NCT07377773Arthritis, Rheumatoid2Not yet recruitingMar 5, 2028180
NCT07344051Moderate-to-severe Atopic Dermatitis2Not yet recruitingSep 2027160
NCT06946641Dermatitis, Atopic · China1RecruitingDec 2025102

How it is read

Names in the registry

  • “QLS12010”, 4 entries

Codes read as this program: QLS12010.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.